ClinicalTrials.gg
Not yet recruitingNCT07950553Updated Nov 20, 2026

Slider Versus Tensioner Neural Mobilization Techniques in Carpal Tunnel Syndrome

An interventional study of slider neural mobilization techniques and tensioner neural mobilization in Carpal Tunnel Syndrome (CTS), sponsored by Prince Sattam Bin Abdulaziz University. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Prince Sattam Bin Abdulaziz University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

neural mobilization techniques in carpal tunnel syndrome

Read the detailed description

Thirty patients with CTS will be randomly allocated to two equal groups of 15. Group A will receive slider median nerve mobilization techniques and Group B received tensioners median nerve mobilization techniques , twice a week for 10 weeks

02

Conditions studied

  • Carpal Tunnel Syndrome (CTS)

Keywords

  • Carpal Tunnel Syndrome
  • slider tecniques
  • tensioner tecniques
  • pressure pain threshold
  • hand grip strength
03

In context

Carpal Tunnel Syndrome

591 studies on the registry are indexed under Carpal Tunnel Syndrome; 133 are open to participants now.

This study's planned enrollment of 30 is below the median of 60 across 446 interventional studies indexed under Carpal Tunnel Syndrome.

Browse Carpal Tunnel Syndrome studies →

Lead sponsor

Prince Sattam Bin Abdulaziz University is the lead sponsor of 36 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of Alzheimer's Disease
  • Must be able to swallow tablets

Exclusion criteria

Exclusion Criteria:

  • received physiotherapy or a injection for CTS in the previous 3 months
  • have CTS secondary to a chronic systemic disease such as diabetes mellitus, hypothyroidism or rheumatoid arthritis
  • had previous wrist surgery
  • have cervical radiculopathy or severe polyneuropathy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    group A

    slider median nerve mobilization tecnique

    Other: slider neural mobilization techniques

  • Experimental
    group b

    tensioner median nerve mobilization techniques

    Other: tensioner neural mobilization

Interventions

  • Otherslider neural mobilization techniques

    patients in group A recieve slider median nerve mobilization

  • Othertensioner neural mobilization

    patients in group recieve tensioner median nerve mobilization techniques

06

What researchers measure

Primary outcomes

  1. pain intensity

    pain intensity will be measured by visual analogue scale

    Time frame: 10 weeks

Secondary outcomes

  1. functional disability

    it will be assessed by the arabic version of DASH questionnaire

    Time frame: 10 weeks

  2. hand grip strength

    it will be assessed by HHD

    Time frame: 10 WEEKS

  3. Pressure pain threshold

    It will be assessed by pressure algometry

    Time frame: 10 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Arman S, Menekseoglu AK, Sezgin B, Ozgur B, Capan N, Oral A. The effects of virtual reality-mediated tendon and nerve gliding exercises in the conservative management of carpal tunnel syndrome: a double-blind randomized placebo controlled trial. Eur J Phys Rehabil Med. 2024 Jun;60(3):458-469. doi: 10.23736/S1973-9087.24.08432-6. Epub 2024 Mar 29. PubMed 38551521 ↗
  • Beddaa H, Kably B, Marzouk B, Mouhi I, Marfak A, Azemmour Y, Bouzekraoui Alaoui I, Birouk N. The effectiveness of the median nerve neurodynamic mobilisation techniques in women with mild or moderate bilateral carpal tunnel syndrome: A single-blind clinical randomised trial. S Afr J Physiother. 2022 Nov 30;78(1):1823. doi: 10.4102/sajp.v78i1.1823. eCollection 2022. PubMed 36483131 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Apr 2027, 4 months later.

Of 252 non-industry interventional studies with no phase under Carpal Tunnel Syndrome, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 27. This study's planned 4 months is below that.

Counting every sponsor, half of 262 studies reached it within 12 months; a quarter within 7 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 20, 2026
StartEst.
Dec 5, 2026
Primary completionEst.
Apr 10, 2027
CompletionEst.
Apr 20, 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07950553
Lead sponsor
Prince Sattam Bin Abdulaziz University
Responsible party
Mohammad Moustafa Aldosoukki Hegazy (assisstant professor, Prince Sattam Bin Abdulaziz University) — Principal investigator
First posted
Nov 20, 2026
Start date
Dec 5, 2026 (estimated)
Primary completion
Apr 10, 2027 (estimated)
Completion
Apr 20, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Mohammed Hegazy
Contact
m.hegazy@psau.edu.sa
0566169893

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion